- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Lakewood-Amedex receives patents in Australia, New Zealand | 1 | Investing.com | ||
| 22.05. | Lakewood-Amedex Biotherapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| LAKEWOOD-AMEDEX BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.05. | Lakewood-Amedex Shares Fall 20% Despite Positive Nu-3 Development Update | 12 | RTTNews | ||
| 12.05. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3 | 166 | PR Newswire | Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU market
SARASOTA, Fla., May... ► Artikel lesen | |
| 01.05. | Lakewood-Amedex Biotherapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 01.05. | Lakewood-Amedex reports resistance data for diabetic ulcer drug | 2 | Investing.com | ||
| 28.04. | Lakewood-Amedex beruft CEO von Enveric in den Verwaltungsrat | 3 | Investing.com Deutsch | ||
| 28.04. | Lakewood-Amedex appoints Enveric CEO to board of directors | 3 | Investing.com | ||
| 24.04. | Lakewood-Amedex-Aktie legt bei NASDAQ-Debüt um 20 % zu | 5 | Investing.com Deutsch | ||
| 23.04. | Lakewood-Amedex Biotherapeutics Inc.: Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT" | 320 | PR Newswire | SARASOTA, Fla., April 23, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class... ► Artikel lesen | |
| 17.04. | Lakewood-Amedex Biotherapeutics Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 01.04. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 13.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 05.02. | Lakewood-Amedex Biotherapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 09.01. | Lakewood-Amedex Biotherapeutics Inc. - S-1, General form for registration of securities | - | SEC Filings |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| VALNEVA | 2,331 | -0,64 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| PALATIN TECHNOLOGIES | 14,200 | +3,65 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,210 | +0,83 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,240 | -4,26 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,690 | +0,27 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| XOMA ROYALTY | 36,200 | -1,09 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,580 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones | OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced a significant milestone in its pancreatic cancer development program... ► Artikel lesen | |
| NOVOCURE | 15,175 | +11,05 % | NovoCure Ltd - 8-K, Current Report | ||
| PHARMING | 1,115 | +0,54 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| CYTOKINETICS | 63,00 | +1,58 % | Cytokinetics, Incorporated: Cytokinetics bringt MYQORZO (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland | Auf den erfolgreichen Start in den USA folgt nun die Markteinführung in Europa
SOUTH SAN FRANCISCO, Kalifornien, und ZUG, Schweiz, June 01, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:... ► Artikel lesen | |
| TRAWS PHARMA | 1,380 | +0,73 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen |
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,90 % bei einem Aktienkurs von 0,649 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.